KDM4B Antibody

1. findings illustrate the significance of CREB-KDM4B-STAT3 signaling cascade in DNA damage response, and highlight that KDM4B may potentially be a novel oncotarget for colorectal cancer radiotherapy. PMID:29633065
2. p-ERK-mediated phosphorylation and stabilization of JMJD2B during glucose deprivation contributes to its role in glucose uptake and cell viability, which may be modulated through epigenetically upregulation of GLUT1 in colon cancer cells. PMID:28945223
3. KDM4B may play an important role in mitochondrial apoptosis and represent a potential therapeutic cancer target in colorectal cancer PMID:27506941
4. High KDM4B expression is associated with Neuroblastomas. PMID:28684529
5. This is the first demonstration that a Jumonji-domain histone demethylase regulates cellular processes required for peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to improve existing therapies for EOC patients. PMID:27869162
6. identification of JMJD2B/KDM4B as a p53-inducible gene in response to DNA damage. PMID:28073943
7. KDM4B and KDM4D expression may associate with an aggressive subtype of classical Hodgkin lymphoma and be linked with radioresistance PMID:27630312
8. KDM4B is a key mediator in epithelial-mesenchymal transition process, and may serve as an important prognostic marker and therapeutic target for the metastatic progression of human pancreatic cancer PMID:26511091
9. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. CONCLUSION: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma PMID:27630338
10. upon TGF-beta stimulation, KDM4B was recruited to the SOX9 promoter, removed the silencing H3K9me3 marks, and activated the transcription of SOX9. PMID:26485430
11. High KDM4B expression is associated with endometrial cancer progression. PMID:26397136
12. JMJD2B and JMJD2C play an important role in the pathology of osteosarcoma via the up-regulation of FGF2. PMID:25636512
13. results reveal that JMJD2B is dramatically upregulated in hepatocellular carcinoma, making it a potential diagnostic marker for the further development of HCC treatment therapies PMID:25533242
14. Functional studies demonstrated that KDM4B regulates the Myc pathway. N-Myc was found to physically interact with and recruit KDM4B. KDM4B was found to regulate neuroblastoma cell proliferation and differentiation in vitro and xenograft growth in vivo. PMID:25925418
15. Data indicate that miR-491-5p plays a tumor suppressor role in the development and progression of breast cancer via direct targeting the 3'UTR of JMJD2B mRNA. PMID:25725194
16. Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer. PMID:24957706
17. KDM4B was upregulated in colon and rectal adenocarcinomas and required for efficient growth and clonogenic activity of human HT-29 colon cancer cells. PMID:24481461
18. A novel function of JMJD2B in promoting epithelial-mesenchymal transition and gastric cancer invasion and metastasis. PMID:24077348
19. Results suggest that by regulating JMJD2b and SUV39H1 expression, p53 not only controls transcription but also promotes HC relaxation to accelerate a rate-limiting step in the repair of complex genomes. PMID:23376847
20. Jumonji domain-containing protein 2B has an essential role in cancer cell survival and tumor growth via DNA damage response mediation, which STAT3 partially regulates. PMID:24473398
21. novel pathway by which Hsp90 activity alters the histone code via regulation of KDM4B stability. PMID:23589305
22. JMJD2B may play a central role in gastric cancer cell growth and might constitute a novel therapeutic target to overcome hypoxia-induced radio-resistance, thereby improving the efficiency of radiation therapy. PMID:23046878
23. JMJD2B interacts with ERalpha and components of the SWI/SNF-B chromatin remodeling complex. JMJD2B is recruited to ERalpha target sites, demethylates H3K9me3 and facilitates transcription of ER responsive genes including MYB, MYC and CCND1. PMID:21445275
24. The histone demethylases KDM4B and KDM6B play critical roles in osteogenic commitment of mesenchymal stem/stromal cells. PMID:22770241
25. showed that JMJD2B was overexpressed in colorectal cancer tissues and positively correlated with expression of the hypoxic marker carbonic anhydrase 9 PMID:22745382
26. High JMJD2B is associated with bladder and lung carcinogenesis through positive regulation of cyclin-dependent kinase 6. PMID:21930796
27. JMJD2B is required for sustained proliferation and survival of tumor cells in vitro and in vivo, and its aberrant expression may contribute to the pathogenesis of gastric cancer. PMID:22133676
28. knockdown of JMJD2B severely impairs estrogen-induced cell proliferation and the tumor formation capacity of breast cancer cells PMID:21445275
29. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. PMID:21502505
30. Histone demethylase JMJD2B is regulated by both ERalpha and HIF-1alpha, drives breast cancer cell proliferation in normoxia and hypoxia, and epigenetically regulates the expression of cell cycle genes. PMID:20682797
31. Two GATA-binding sites within intron 6 of human JMJD2B gene were conserved in mouse Jmjd2b gene. PMID:17611647
32. Results show that many genes regulated by hypoxia and HIF-1alpha show patterns of induction with JMJD (Jumonji-domain containing)1A and JMJD2B demonstrating robust, and JMJD2C more modest, up-regulation by hypoxia. PMID:18713068
33. histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF PMID:18984585

Show More

Hide All

HGNC: 29136

UNIGENE: Hs.654816

KEGG: hsa:23030

STRING: 9606.ENSP00000159111

OMIM: 609765